2025
Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline
Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A
Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales
Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors
Epiminder Appoints Mark McLellan as Chief Financial Officer
Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company
Solventum Appoints Heather Knight as Chief Commercial Officer
Solventum; Heather Knight; Chief Commercial Officer; MedTech; Leadership appointment; Chris Barry; MedSurg; Dental Solutions; Health Information Systems; Global commercial operations; R&D
Galapagos Winds Down Cell Therapy Business After Failed Sale, Cuts 365 Jobs and Shutters Global Sites
Galapagos; cell therapy; exit; layoffs; restructuring; site closures
Novo Nordisk CEO and Board Leadership Step Down Amid Market Pressures; New Board to Prioritize Faster Decision-Making
Novo Nordisk; CEO resignation; Lars Fruergaard Jørgensen; board leadership change; Novo Nordisk Foundation; share price decline; strategic decision-making; competition; Lars Rebien Sørensen; executive transition
Companies Struggle to Accelerate Production of Bespoke mRNA Therapies
bespoke mRNA therapies; personalized medicine; manufacturing challenges; cancer vaccines; scalability; manufacturing efficiency; cold chain logistics; regulatory complexity; mRNA production innovation; AI optimization
Rethinking Strategies in Pharma Amidst Supply Chain Disruptions
pharma; supply chain; cost control; capability building
Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued
Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD
Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review
Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission